MedPath
HSA Approval

FLIXOTIDE EVOHALER 125 mcg

SIN11347P

FLIXOTIDE EVOHALER 125 mcg

FLIXOTIDE EVOHALER 125 mcg

July 12, 2000

GLAXOSMITHKLINE PTE LTD

GLAXOSMITHKLINE PTE LTD

Regulatory Information

GLAXOSMITHKLINE PTE LTD

GLAXOSMITHKLINE PTE LTD

Therapeutic

Prescription Only

Formulation Information

AEROSOL, SPRAY

**Dosage and Administration** Pharmaceutical form: Pressurised metered-dose aerosol Patients should be made aware of the prophylactic nature of therapy with inhaled _FLIXOTIDE_ and that it should be taken regularly even when they are asymptomatic. _FLIXOTIDE_ is for inhalation by oral inhalation only. It is intended that each prescribed dose is given by a minimum of two inhalations. In patients who find co-ordination of a pressurised metered dose inhaler difficult, a spacer may be used with _FLIXOTIDE_ inhaler. **ASTHMA** The onset of therapeutic effect is four to seven days, although some benefit may be apparent as soon as 24 hours for patients who have not previously received inhaled steroids. If patients find that relief with short-acting bronchodilator treatment becomes less effective or they need more inhalations than usual, medical attention must be sought. - **Adults and children over 16 years of age** 100 to 1000 micrograms twice daily. Patients should be given a starting dose of inhaled FLIXOTIDE which is appropriate for the severity of their disease: Mild asthma:-100 to 250 micrograms twice daily.Moderate asthma:-250 to 500 micrograms twice daily.Severe asthma:-500 to 1000 micrograms twice daily. The dose may then be adjusted until control is achieved or reduced to the minimum effective dose, according to the individual response. Alternatively, the starting dose of fluticasone propionate may be gauged at half the total daily dose of beclomethasone dipropionate or equivalent as administered by metered-dose inhaler. - **Children 4 years of age and over** 50 to 100 micrograms twice daily. Children should be given a starting dose of inhaled _FLIXOTIDE_ that is appropriate for the severity of the disease. The dose may then be adjusted until control is achieved, or reduced to the minimum effective dose, according to individual response. It should be noted that only the 50 microgram device is suitable for the administration of this dose. This presentation of _FLIXOTIDE_ may not offer the required paediatric dose, in which case an alternative presentation of _FLIXOTIDE_ should be considered (e.g. dry powder inhalers). - **Children aged 1 to 4 years** Inhaled _FLIXOTIDE_ is of benefit to younger children in the control of frequent and persistent asthma symptoms. Clinical trials in 1 to 4 year old children have shown that the optimal control of asthma symptoms is achieved with 100 micrograms twice daily, administered via a paediatric spacer device with a face mask (such as the _BABYHALER_ ™). The diagnosis and treatment of asthma should be kept under regular review. - **Special patient groups** There is no need to adjust the dose in elderly patients or in those with hepatic or renal impairment.

RESPIRATORY (INHALATION)

Medical Information

**Indications** **ASTHMA** _FLIXOTIDE_ has a marked anti-inflammatory effect in the lungs. It reduces symptoms and exacerbations of asthma in patients previously treated with bronchodilator alone or with other prophylactic therapy. Severe asthma requires regular medical assessment as death may occur. Patients with severe asthma have constant symptoms and frequent exacerbations, with limited physical capacity, and PEF values below 60% predicted at baseline with greater than 30% variability, usually not returning entirely to normal after a bronchodilator. These patients will require high dose inhaled ( _see Dosage and Administration_) or oral corticosteroid therapy. Sudden worsening of symptoms may require increased corticosteroid dosage which should be administered under urgent medical supervision. - **Adults** Prophylactic management in: - Mild asthma (PEF values greater than 80% predicted at baseline with less than 20% variability): Patients requiring intermittent symptomatic bronchodilator asthma medication on more than an occasional basis. - Moderate asthma (PEF values 60–80% predicted at baseline with 20–30% variability): Patients requiring regular asthma medication and patients with unstable or worsening asthma on currently available prophylactic therapy or bronchodilator alone. - Severe asthma (PEF values less than 60% predicted at baseline with greater than 30% variability): Patients with severe chronic asthma. On introduction of inhaled _FLIXOTIDE_, many patients who are dependent on systemic corticosteroids for adequate control of symptoms may be able to reduce significantly or to eliminate their requirement for oral corticosteroids. - **Children** Any child who requires preventative asthma medication, including patients not controlled on currently available prophylactic medication.

**Contraindications** Hypersensitivity to any ingredient of the preparation.

R03BA05

fluticasone

Manufacturer Information

GLAXOSMITHKLINE PTE LTD

GLAXO WELLCOME PRODUCTION

Glaxo Wellcome S.A.

Active Ingredients

FLUTICASONE PROPIONATE

125 mcg

Documents

Package Inserts

Flixotide 125mcg PI.pdf

Approved: February 3, 2023

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

FLIXOTIDE EVOHALER 125 mcg - HSA Approval | MedPath